Roche's headquarters in Basel, Switzerland (Kyle LaHucik for Endpoints News)
ODAC to debate Roche's Polivy in first-line DLBCL following 2019 accelerated approval
Once again the FDA’s panel of outside oncology experts will have to weigh in on whether or not to grant another indication for Roche’s potential …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
